Clinical Trial Search

Primary: Difference in PD2 (Provocative Dose of Aspirin That Elicits an Increase in Nasal Symptom Score of 2 During an Aspirin Challenge) on Prasugrel Versus Placebo — 79; 139 mg

Primary: Urinary Levels of Cys-Leukotrienes — 874.05; 771.99 pg/ml

Primary: Change From Baseline in Sinonasal Outcome Test-22 Score — -6.7; -13.7 units on a scale

Primary: Proportion of Patients Who Experience a ≥ 20% Decrease in Forced Expiratory Volume in One Second (FEV1) Compared to Baseline Following a Dose of Investigational…

Primary: Provocative Dose 2 (PD2) During Aspirin Challenge — 121; 142 mg

Primary: Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Post-dose in Patients With Exercise-Induced Bronchoconstriction…

Primary: Number of Subjects With Serious Adverse Events — 0; 0 participants

Primary: Number of Participants Without Respiratory Reaction During Aspirin Desensitization — 0; 5 Participants — p=0.036

Primary: Asthma Control — 312; 72; 0; 229 Participants

Primary: Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 24 Hours — 0.793; 1.950; 2.504; 3.236 Log base 2…

Primary: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) — 24.4; 18.0; -1.4 Liters per minute

Primary: Number of Participants Who Developed Acute Respiratory Distress Syndrome (ARDS) Within 7 Days — 20; 17 participants — p=0.53

Primary: Maximum Percent Fall in FEV1 After Exercise Challenge at 2 Hours Postdose Compared With Pre-exercise Baseline in Patients With Exercise-induced Bronchospasm (EIB)…

Primary: Change in Exhaled Inflammatory Mediator Levels — 1.42 pg/mL

Primary: Maximum Percent Fall in FEV1 After Exercise Challenge at 2 Hours Post-dose Compared With Pre-exercise Baseline in Patients With Exercise-induced Bronchospasm (EIB)…

Primary: FEV1 Percent Change Post-ipratropium — 10.8 percent change — p=0.032

Primary: Change in Forced Expiratory Volume in 1 Second (FEV1) — -24.66; -8.44; -9.15; -16.17 Percentage drop in FEV1 — p=<0.0001

Primary: Change in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge — 0.822; 6.468 Percent — p=0.0208

Primary: Maximum Percent Drop From Pre-allergen Baseline in Forced Expiratory Volume in 1 Second (FEV1) for Late-Phase Asthma Response (LAR) at Screening — 27.19; 20.47 percent…

Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage

Primary: Change in Asthma Control Test Score — 3.32 change in composite score

Primary: Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period — 0.99; 1.06; 1.05 Asthma attacks within episodes per year — p=0.510

Primary: Time to First Severe Exacerbation — 43.75; 49.43 Days — p=0.758

Primary: Forced Expiratory Volume in One Second (FEV1) % Predicted Trough Change From Baseline (Mean Observed in the 2 Weeks Prior to Treatment) After Six Weeks of Treatment…

Primary: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3 — 9.53; 9.15 Percent Change

Primary: Percentage Change of Area Under Curve for the Urinary Prostaglandins Concentration Versus Time Curve (AUC) in Response to Aspirin or Placebo — 95; 43 Percentage change…

Primary: Baseline-adjusted FEV1 30 Minutes After Each Cumulative Dose — 0.421; 0.488; 0.548; 0.586 Liter

Primary: Changes in a Smoking-related Gene Expression Signature Score in the Nasal Epithelium of Current Smokers — -0.15; 0.26 score on a scale

Primary: Maximum Post-exercise Percent (%) Fall in FEV1 — 10.57; 13.82 Percent change from baseline — p=0.009

Primary: 16 Weeks - Juniper Asthma Quality of Life Questionnaire (AQLQ) Score — 4.7; 4.6 units on a scale